QNRX NASDAQ
Quoin Pharmaceuticals, Ltd.
1W: -14.8%
1M: -17.3%
3M: -45.4%
YTD: -63.3%
1Y: -32.9%
3Y: -97.5%
5Y: -100.0%
$4.94
-0.23 (-4.45%)
Weekly Expected Move ±9.8%
$5
$5
$6
$7
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.9M
52W Range4.81-41.8
Volume14,515
Avg Volume96,572
Beta1.62
Dividend—
Analyst Ratings
Company Info
CEOMichael Myers
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2016-08-01
Websitequoinpharma.com
42127 Pleasant Forest Court
Ashburn, VA 20148-7349
US
Ashburn, VA 20148-7349
US
703 980 4182
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Latest News
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
What is Zacks Research’s Forecast for QNRX Q1 Earnings?
12 Health Care Stocks Moving In Friday's Pre-Market Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Stonepine Capital Ma | 0 | — | 2026-03-26 | |
| Lawlor Sally Bridget | A-Award | 85,250 | $7.37 | 2026-02-04 |
| Cooper Joseph Patric | A-Award | 8,141 | $7.37 | 2026-02-04 |
| Culverwell Anthony J | A-Award | 21,709 | $7.37 | 2026-02-04 |
| Myers Michael | A-Award | 318,750 | $7.37 | 2026-02-04 |